The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region for the three and nine months ended September 30, 2018 and 2017. The information for the three and nine months ended September 30, 2017 has not been adjusted in accordance with our modified retrospective adoption of Topic 606 and continues to be reported in accordance with our historical accounting under Topic 605.



	Three Months Ended September 30, 2018								Three Months Ended September 30, 2017
(In millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product sales:
Atripla	$	221	$	29	$	8	$	258	$	324	$	79	$	36	$	439
Biktarvy	375		11		—		386		—		—		—		—
Complera/Eviplera	61		67		11		139		91		133		13		237
Descovy	310		81		15		406		241		65		10		316
Genvoya	921		203		52		1,176		810		146		32		988
Odefsey	323		95		5		423		255		37		4		296
Stribild	111		20		15		146		181		40		8		229
Truvada	665		62		30		757		604		154		53		811
Other HIV⁽¹⁾	10		2		2		14		13		2		—		15
Revenue share - Symtuza⁽²⁾	8		14		—		22		—		—		—		—
AmBisome	9		59		34		102		9		51		32		92
Epclusa	225		136		116		477		543		263		76		882
Harvoni	185		38		88		311		718		110		145		973
Letairis	241		—		—		241		213		—		—		213
Ranexa	178		—		—		178		164		—		—		164
Vemlidy	66		2		19		87		34		2		1		37
Viread	17		10		43		70		137		55		82		274
Vosevi	78		21		4		103		117		5		1		123
Yescarta	75		—		—		75		—		—		—		—
Zydelig	15		4		1		20		18		22		—		40
Other⁽³⁾	37		19		8		64		70		33		170		273
Total product sales	4,131		873		451		5,455		4,542		1,197		663		6,402
Royalty, contract and other revenues	20		102		19		141		21		74		15		110
Total revenues	$	4,151	$	975	$	470	$	5,596	$	4,563	$	1,271	$	678	$	6,512



	Nine Months Ended September 30, 2018								Nine Months Ended September 30, 2017
(In millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product Sales:
Atripla	$	723	$	119	$	79	$	921	$	974	$	259	$	133	$	1,366
Biktarvy	593		13		—		606		—		—		—		—
Complera/Eviplera	210		279		39		528		315		385		44		744
Descovy	895		234		41		1,170		682		149		22		853
Genvoya	2,678		596		144		3,418		2,189		358		67		2,614
Odefsey	905		230		15		1,150		688		87		6		781
Stribild	388		83		36		507		632		161		38		831
Truvada	1,821		245		108		2,174		1,635		527		175		2,337
Other HIV⁽¹⁾	30		6		10		46		34		5		2		41
Revenue share - Symtuza⁽²⁾	8		34		—		42		—		—		—		—
AmBisome	40		170		102		312		26		153		97		276
Epclusa	733		502		278		1,513		2,142		649		154		2,945
Harvoni	649		116		225		990		2,628		583		515		3,726
Letairis	689		—		—		689		654		—		—		654
Ranexa	581		—		—		581		517		—		—		517
Vemlidy	172		8		41		221		66		3		1		70
Viread	40		72		137		249		395		202		237		834
Vosevi	250		57		12		319		117		5		1		123
Yescarta	183		—		—		183		—		—		—		—
Zydelig	46		44		2		92		52		57		1		110
Other⁽³⁾	93		75		117		285		228		279		496		1,003
Total product sales	11,727		2,883		1,386		15,996		13,974		3,862		1,989		19,825
Royalty, contract and other revenues	54		233		49		336		62		226		45		333
Total revenues	$	11,781	$	3,116	$	1,435	$	16,332	$	14,036	$	4,088	$	2,034	$	20,158

____________________
⁽¹⁾ Includes Emtriva and Tybost
⁽²⁾Represents Gilead’s revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen
⁽³⁾ Includes Cayston, Hepsera and Sovaldi